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Abstract
Numerous randomized controlled trials (RCTs) have demonstrated the glycemic benefits of continuous glucose
monitoring (CGM) in management of type 1 diabetes (T1D) and type 2 diabetes. Although RCTs remain the
gold standard clinical study design, findings from these trials do not necessarily reflect the effectiveness of
CGM or reveal the feasibility and wider applications for use in broader real-life settings. This review evaluates
recent real-world evidence (RWE) demonstrating the value of CGM to improve clinical outcomes, such as
avoidance of severe hypoglycemic and hyperglycemic crises, and improved measures of psychological health
and quality of life. Additionally, this review considers recent RWE for the role of CGM to enhance health care
resource utilization, including prediction of T1D and applications in gestational diabetes, chronic kidney dis-
ease, and monitoring during surgery.
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Introduction
Well-designed, randomized controlled trials(RCTs) have traditionally been considered the highest
level of trial evidence. Although they provide critical infor-
mation about the efficacy of a given intervention (medication
or medical device) when applied within tightly controlled
clinical conditions, the results may not replicate how or if
individuals will actually integrate the intervention into their
daily lives, potentially resulting in an overestimation of ef-
ficacy. Moreover, RCTs may not reflect the effects of an
intervention within the populations that have been excluded
from the trial.
Another limitation of RCTs concerns the assessment of
rapidly evolving diabetes technologies in meta-analyses and
systematic reviews (MASRs). By the time enough studies
have been completed for a robust MASR, subsequent im-
provements in accuracy, reliability, and convenience will
render the results from MASRs outdated and potentially
misleading in terms of the efficacy and safety of current
technologies. This is particularly relevant to continuous
glucose monitoring (CGM).
Given these limitations, there is growing recognition for
the role of real-world evidence (RWE) generated by pro-
spective, retrospective, and observational studies that fill the
knowledge gap between the responses of individuals to an
intervention within a controlled setting compared with pat-
terns of response and clinical impact in real life. Recognizing
the importance of real-world study designs, many payers and
regulatory agencies now request pharmaceutical and medical
device manufacturers to submit RWE in conjunction with
findings from their RCTs when assessing the safety, effec-
tiveness, and cost–benefit parameters of new medications and
medical devices.1–4
Over the past decade, findings from several large RCTs
have demonstrated the clinical value and utility of improving
the overall glycemic status5–10 and reducing hypoglycemia
risk5,7,11–13 in individuals with type 1 diabetes (T1D) and type 2
diabetes (T2D) who are treated with intensive insulin regi-
mens. In this article, we review findings from recent real-world
studies of CGM systems that provide greater insights into the
clinical effectiveness and economic impact of this technology
within various diabetic populations. We also discuss how CGM
is being used to expand our understanding of diabetes in toto.
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Evidence of Clinical Effectiveness
As adoption of CGM continues to expand, we are seeing a
growing number of large national and commercial database
studies investigating the effects of CGM on A1C, hypogly-
cemia risk, and acute diabetes-related events in individuals
with T1D14–24 and T2D.25–27
Table 1 presents a summary of findings from the most
recent real-world studies within the past 2 years.
T1D studies
A recent, prospective observational study assessed the
impact of using flash CGM (FreeStyle Libre, Abbott Diabetes
Care, Alameda, CA) in a cohort of 1913 T1D adults.15 During
the 12-month study period, there was a significant reduction
in admissions for severe hypoglycemia and/or ketoacidosis
(from 3.3% to 2.2%, P = 0.031), with fewer individuals re-
porting severe hypoglycemic events (from 14.6% to 7.8%,
P < 0.0001). Reductions in the percentages of individuals
who experienced hypoglycemic coma (from 2.7% to 1.1%,
P = 0.001) and reported work absenteeism (from 5.8% to
2.9%, P < 0.0001) were also observed. Results from an earlier
study showed similar findings among patients using other
CGM devices, namely MiniMed Enlite (Medtronic, Inc.,
Northridge, CA); G4 PLATINUM (Dexcom, Inc., San Diego,
CA); and FreeStyle Navigator II (Abbott Diabetes Care).14
The use of these devices also showed favorable results in
improving A1C, reducing hypoglycemia events and hospi-
talizations, and decreasing days absent from work.
Similar findings emerged from an analysis of a large Dutch
registry that included 1365 individuals with diabetes, the
majority of whom had T1D (77%).16 Investigators reported
that use of flash CGM was associated with significant A1C
reductions after 12 months (from 8.0% to 7.4%, P < 0.001).
Significant reductions in the percentage of patients expe-
riencing any hypoglycemic event (from 93.1% to 91.0%,
P < 0.05) and a decrease in the number of diabetes-related
hospitalizations (from 144 to 22, P < 0.001) were also ob-
served along with reductions in work absenteeism (from
18.6% to 7.8%, P < 0.001).
In a single-center cohort of 41 participants with T1D (aged
5–49 years), investigators assessed the long-term effects of
initiating CGM (FreeStyle Libre, Dexcom G4, and MiniMed
Guardian Sensor 3) in conjunction with insulin pump therapy
on A1C and the incidence of hypoglycemia and microvas-
cular disease. At follow-up (8.9 – 2.8 years), A1C had de-
creased from 8.8% to 7.6% (P = 0.051), with significant
reductions in severe hypoglycemia (from 9.7 to 2.2 per 100
patient-years, P = 0.03), but with a comparable incidence of
newly diagnosed, diabetic microvascular complications.32
Similar A1C reductions were observed in a prospective
observational study that assessed A1C changes in 900 adult
T1D patients using flash CGM compared with 518 patients
who continued usual care with traditional blood glucose
monitoring (BGM).18 Users of flash CGM with a baseline
A1C >7.5% showed a significant reduction of A1C over an
8-month study period (median -0.6%, P < 0.001), whereas no
changes in A1C were observed with BGM use. Among flash
CGM users, there was a 48.8% increase in those achieving
an A1C <7.5% and the number of those with an A1C >9.0%
was more than halved. Although flash CGM users reported
more symptomatic and asymptomatic hypoglycemia, this is
likely to derive from heightened awareness due to having
access to continuous glucose data through frequent scan-
ning. Importantly, there were no significant changes in severe
hypoglycemia.
An earlier study of 120 T1D adults who were followed for
12 months after initiating flash CGM found significant de-
creases in A1C levels from baseline at 3 months (from 8.5%
to 7.8%, P < 0.001), but with a slight increase to 7.9% at
12 months.22 These improvements were accompanied by
reduction in fear of hypoglycemia, which is often a major
obstacle to achieving optimal glycemic control.33,34 As noted
in some other studies,21 there was a slight, but statistically
significant, (P < 0.05) increase in the number (but not dura-
tion) of hypoglycemic events at 12 months, which correlated
with improvements in A1C and may be attributed largely
to awareness with use of CGM. However, in a prospective
observational study that compared flash CGM with BGM
use in a cohort of 334 T1D children/adolescents, there was a
53% (P = 0.012) reduction in cases of severe hypoglycemia
among users of flash CGM compared with those using BGM,
although A1C was not significantly altered in either group.35
The majority (83.2%) of patients who switched from BGM to
using flash CGM were still using their device after median
use of 5.3 months.
T2D studies
About 20%–30% of patients with T2D eventually require
insulin therapy, enabling substantial reductions in A1C lev-
els, acute diabetes-related adverse events (ADEs), and all-
cause hospitalizations (ACHs).21,27 Although a majority of
insulin-treated T2D patients receive only basal insulin with
or without other glucose-lowering agents (rather than basal–
bolus injections or pump therapy), CGM still offers an op-
portunity to optimize glycemic control.
A retrospective chart review of 363 T2D adults from three
European countries assessed the effectiveness of flash CGM
use in conjunction with basal–bolus therapy.21 After >90
days following initiation of flash CGM, A1C levels were
significantly lower: -0.9% (Austria), -0.8% (France), and
-0.9% (Germany), all P < 0.0001. The impact of this mag-
nitude of A1C reductions after acquiring a flash CGM device
is reflected in findings from an analysis of IBM MarketScan
Commercial Claims and Medicare Supplemental databases.27
This retrospective real-world analysis of a cohort of 2463
T2D adults treated with short- or rapid-acting insulin noted
significant reductions in ADEs (from 0.180 to 0.072 events/
patient-year, P < 0.001) and ACHs (from 0.420 to 0.283
events/patient-year, P < 0.001) during the 6 months after
acquiring their flash CGM device compared with the 6-month
period before acquisition. These improvements occurred re-
gardless of age or gender.
Recent studies of flash CGM in T2D adults treated with
nonintensive therapies have shown similar findings.30,31 In
a Canadian chart review of 91 T2D adults managed with
basal insulin therapy, there were significant A1C reductions
(-0.8%, P < 0.0001) after 3–6 months of flash CGM use.30 A
subgroup analysis comparing patients with baseline A1C of
<9.0% and >9.0% showed clinically significant A1C reduc-
tions in both groups, but with most notable reductions oc-
curring in the higher A1C group (-1.6%, P < 0.0001). A U.S.
chart review study of 100 T2D adults treated with basal
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































insulin therapy showed similar reductions in A1C after 3–6
months of flash CGM, with the largest reductions (-1.7%,
P < 0.0001) seen in those with baseline >9.0 A1C.31
Findings of decreased rates of ADEs and ACHs have also
been reported in a cohort of 10,282 adult T2D patients treated
with nonintensive or noninsulin therapy.25 Retrospective
analysis of the MarketScan databases revealed significant
decreases in ADEs and ACHs at 6 months postacquisition of
a flash CGM device (from 0.076 to 0.052 events/patient-year,
P < 0.001, and from 0.177 to 0.151 events/patient-year, P =
0.002, respectively). Using a similar study design, an analysis
of the Explorys commercial databases assessed the impact of
flash CGM acquisition in 1034 poorly controlled T2D adults
(baseline A1C 10.1%) treated with basal insulin (n = 306) or
noninsulin therapy (n = 728).26 At 6 months postacquisition
of a flash CGM device, significant reductions in A1C were
observed in the basal insulin group (-1.1%) and noninsulin
treatment group (-1.6%), both P < 0.001.
Intermittent use of CGM has also been demonstrated
to improve glycemic control in T2D patients treated with
less-intensive therapies. Findings from two studies, which
assessed changes in A1C in T2D adults enrolled in the Onduo
Virtual Diabetes Clinic telehealth program, showed that in-
termittent use of CGM was strongly associated with sig-
nificant reductions in A1C.36,37 In 55 patients with mean
baseline A1C of 8.9%, intermittent use of the Dexcom G5
device resulted in a 1.6% reduction in A1C from baseline
(P < 0.001).36 In a larger study (n = 372) of an Onduo popu-
lation with 7.7% A1C at baseline, Bergenstal et al. observed a
smaller, but significant, reduction (-0.6%, P < 0.001) from
baseline.37 However, the reduction among those with >9.0%
baseline A1C was notably greater (-2.6%, P < 0.001).
Inpatient outcomes
Achieving and maintaining glycemic control in critically
ill patients have been shown to profoundly impact clinical
outcomes,38 especially in patients with diabetes and patients
being treated with insulin infusions for hyperglycemic crises
such as diabetic ketoacidosis or hyperosmolar hyperglycemic
state.39 Managing glycemic status also plays an important
role in reducing viral load and infection duration in patients
with diabetes.40
As demonstrated in a single-center cohort study of 44
patients with diagnosed T2D and 16 with new-onset hyper-
glycemia,41 glycemic metrics were improved, and composite
complications were reduced when using flash CGM during
insulin treatment. Across the 190,080 available CGM data
points, 72.5% of values were within the target glucose
range of 70–180 mg/dL, 22% were >180 mg/dL, and 3% were
<70 mg/dL. During treatment, the coefficient of variation
(% CV) was 30%. Although no associations between time in
range (TIR) and the composite complications were observed,
patients who spent more time with glucose >180 mg/dL had
higher complication rates than those who maintained target
glucose levels (22.5% vs. 16%, P = 0.04).
In another single-center cohort study, CGM data (Dexcom
G6) from 30 diabetic patients during the first 24 h of admis-
sion to intensive care with severe coronavirus disease 2019
(COVID-19) infection were compared with glucose values
from arterial line point-of-care (POC) values.42 CGM data
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of POC values, and although some discordance between
CGM and POC values was observed in 11 patients, the dif-
ferences were not considered clinically significant. During
the observation period, mean sensor glucose decreased from
235.7 – 42.1 mg/dL to 202.7 – 37.6 mg/dL with the use of
CGM. Additionally, most (63%) of the attending nurses
reported that CGM was helpful for improving patient care
and 49% indicated that use of CGM reduced their personal
protective equipment utilization.
Improvements in psychosocial measures
In many of the current studies that showed significant as-
sociations between CGM use and improvements in glycemic
measures, investigators have also reported increased treat-
ment satisfaction,15,20 less hypoglycemia fear,20,22 enhanced
sense of well-being,20 and improvements in other health-
related measures15,16,18–20 associated with CGM use. For
example, further analysis of a cohort of mostly T1D indi-
viduals described earlier16 found improvements in quality of
life (QoL) measures and better patient engagement with their
self-management regimens.43 Flash CGM users reported
reduced diabetes burden, as assessed with the SF-12v2 and
EQ-5D-3L questionnaires. Participants also reported more
frequent insulin dose adjustments (80%) and less worry about
their diabetes among family members (62%). The majority
(81.7%) stated that they felt no inhibitions about measuring
their glucose in the presence of strangers.
Studies that focused primarily on QoL outcomes in T1D
children, adolescents, and young adults using CGM have
shown similar improvements in psychosocial measures, in-
cluding significant improvements in overall QoL (P = 0.014),
lessening of diabetes symptoms (P = 0.018), and reduc-
tions in barriers to treatment (P = 0.035).19 In a 2019 study
of 33 T1D adolescents and young adults, investigators re-
ported significant increases in treatment satisfaction and
overall well-being, both P < 0.001, after 12 weeks of flash
CGM use.20
An Australian study that recruited 38 T1D adolescents
(aged >12 years) and their parents (n = 60) assessed changes
in psychosocial measures after 2 months of CGM use.44
Among parents, significant reductions in the total hypogly-
cemia fear score and worry subscore were observed (both
P = 0.004), with improvements in reported sleep quality.
Treatment satisfaction increased in both the patient and par-
ent groups, and significant reductions in the Gold hypogly-
cemia awareness score were reported (from 26.3% to 10.5%,
P = 0.031).
Use of advanced CGM features
Innovations in CGM technologies have resulted in a num-
ber of advanced features that have been shown to improve
glycemic control and reduce hypoglycemia risk in individ-
uals with T1D and T2D. For example, in a retrospective
analysis of 15,000 T1D children and adolescents, 94.8% of
whom used the Dexcom sharing feature,45 use of this feature
was associated with lower mean glucose values, a higher per-
centage of time spent in the target glucose range (70–180 mg/
dL), and fewer episodes of hypoglycemia and hyperglycemia.
A recent study of the Guardian Connect System with the
MiniMed Enlite sensor retrospectively analyzed CGM data
from individuals with T1D (n = 2692), T2D (n = 93), or ges-
tational diabetes (n = 5). When patients utilized the predictive
alerts function, 59% of low glucose excursions and 39% of
high glucose excursions were prevented.46
Studies that Inform Clinicians and Guide Therapy
In addition to improving daily self-management, CGM
has broadened our appreciation of risk factors and clinical
assessments associated with diabetes.
Risk factors
Gender differences in hypoglycemia risk were examined in
a post hoc analysis of a single-center prospective trial of 102
adult T2D inpatients (male, n = 52; female, n = 50) treated
with intensive insulin therapy.47 Patients underwent a stan-
dard bread meal test at baseline and were monitored with
CGM during the last 4 of 7 days on insulin pump therapy.
Although male patients required lower doses of insulin to
maintain optimized glycemic control, they spent more time
with glucose levels <70 mg/dL than their female counterparts
(3.2% vs. 0.9%, P < 0.01%, respectively), with a higher of
incidence of hypoglycemia (20/52 vs. 9/50, P = 0.022).
A study of CGM in 77 women with gestational diabetes
(GDM) investigated whether specific patterns of hyperglyce-
mia at different times of the day could predict maternal–fetal
complications.48 After placing the women on prospective
CGM for 6 days between 26 and 32 weeks of gestation, in-
vestigators observed a statistically significant relationship
between the time spent in hyperglycemia after lunch and fetal
complications, including macrosomia (P = 0.035) and large-
for-gestational age infants (P = 0.010). There was also a 24%
increase in the probability of initiating glucose-lowering
therapies for every additional percentage point of time above
range.
CGM has also been used to predict glycemic control based
on socioeconomic status based on the Index of Relative
Socio-economic Disadvantage (IRSD),49 which measures
disadvantage (e.g., poverty, deprivation, and social exclu-
sion) at an area level (e.g., neighborhood and community),
not at an individual level.50 Among 300 adult T2D patients
assessed in the General Practice Optimising Structured
Monitoring To Improve Clinical outcomes (GP-OSMOTIC)
randomized study, glucose data from the FreeStyle Libre Pro
CGM system revealed that those who were least disadvan-
taged had higher TIR and lower A1C values than those who
were most disadvantaged.51 However, there was no associ-
ation between the educational level and glycemic status.
CGM has been used to assess the appropriateness of a
hospital protocol for managing patients postcardiovascular
surgery.52 Glycemic variability was recorded in 76 patients
during elective cardiovascular surgery and postoperative
management with continuous intravenous insulin infusion in
the intensive care unit (ICU) and when injection therapy was
introduced after oral food intake was initiated. While the
study confirmed that the protocol was adequate during con-
tinuous subcutaneous insulin infusion treatment, it exposed
changes needed to improve the injection therapy protocol.
Assessments
Although measurements of A1C and fructosamine are
often used to monitor glycemic status in individuals without
chronic kidney disease, these methods are limited in their
S-24 GAVIN AND BAILEY
utility to predict the risk of acute glycemic events and to
assess glycemic control in patients treated with dialysis. In a
prospective study of 104 T2D patients with end-stage renal
disease, blinded CGM was recorded for two 6-day periods
separated by 2 weeks, in conjunction with A1C and fructo-
samine measurements.53 When compared with CGM data,
fructosamine was significantly biased by age, body–mass
index, serum iron concentration, transferrin saturation, and
albuminuria. In addition, A1C values were underestimated
in patients with albuminuria.
The utility of CGM in predicting the onset of T1D was
assessed in 23 antibody-positive (Ab+) participants in the
Diabetes Autoimmunity Study in the Young (DAISY), which
prospectively follows children who are at increased risk for
developing islet autoantibodies and T1D.54 Investigators
found that spending ‡18% of time at >140 mg/dL was a
strong predictor of progression to clinical diabetes in Ab+
children. These findings are particularly valuable in light
of the development of new medications such as anti-CD3
monoclonal antibodies that have been shown to delay pro-
gression to T1D in high-risk individuals.55,56
Conclusions
Large RCTs have clearly demonstrated the benefits of
CGM use in individuals with diabetes who are treated with
intensive insulin therapy.5–13 A growing number of real-
world observational and prospective studies are confirming
these findings and demonstrating similar benefits in T2D
patients who are treated with less-intensive therapy.25,26,30,31
Results from these studies suggest that wider use of CGM
within the broader diabetic population could increase over-
all glycemic control and improve the effectiveness while
reducing the enduring cost of diabetes health care. Moreover,
as studies emerge to further elaborate on the utility of CGM
to identify risk of complications, improve care of inpati-
ents, and predict the development and progression of T1D,
we anticipate applications of CGM in broader disease man-
agement and research.
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